HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PCPC Legal Head Tom Myers Steps Into President, CEO Role In 2024

Executive Summary

Personal Care Products Council VP for legal and regulatory affairs and general counsel, Tom Myers, will take over as president and CEO of the US trade association when long-time head Lezlee Westine steps down at the end of the year, the association announced on 15 November.

You may also be interested in...



FDA’s Bumpus Will Be Principal Deputy Commissioner; Cosmetics Industry Reacts With Congratulations, Questions

Chief scientist Namandjé Bumpus will replace Janet Woodcock as principal deputy commissioner at the US FDA when the latter steps down in early 2024. The Personal Care Products Council says Bumpus will continue to lead MoCRA implementation efforts while a new chief scientist is sought, but those and other details remain fuzzy.

FDA Has Early Holiday Gift For Cosmetics Industry: More Time To Register Under MoCRA

The US Food and Drug Administration will delay enforcement of the first registration deadline for cosmetic facility manufacturers and cosmetic product listings under the Modernization of Cosmetics Regulation Act until 1 July, 2024.

CIR Panel’s ‘Ethereal’ Role In Cosmetics Regulation Not Clarified By MoCRA

While other legislative proposals to update US cosmetics regulations would have included FDA ingredient review or codified reviews from the CIR Expert Panel for Cosmetic Ingredient Safety, the Modernization of Cosmetic Regulations Act of 2022 does not. Panelists, industry and FDA reps discussed implications for CIR at the 5-6 March meeting of the group’s independent expert panel.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS154201

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel